Asia Pacific Anaphylaxis Treatment Market

Market Introduction

Anaphylaxis is an allergic reaction that can further lead to a fatal condition known as anaphylactic shock. Anaphylaxis occurs when the patient's body reacts to a foreign substance and produces a high amount of histamine that triggers an inflammatory response. It is a severe, life threatening allergic reaction marked by indications such as swallowing and breathing difficulties, skin itching, and lowering blood pressure.

Thus, the rising incidence of anaphylaxis is expected to create a significant demand for anaphylaxis treatment in the coming years, which is further anticipated to drive the anaphylaxis treatment market.

Certainly, COVID-19 increases the risk of aggravating asthma and allergic diseases, but the government and private agencies are guiding for the treatments. According to guidelines of the Korean Academy of Asthma, Allergy and Clinical Immunology, and the Korean Academy of Pediatric Allergy and Respiratory Disease, detailed monitoring and optimal treatment with AIT, ICS, and biologics need to be continued in all patients who have asthma and allergic diseases. This can be achieved in a safe condition using optimal protective measures. Patients at high risk (older age and comorbid conditions) should be monitored more strictly. All the allergy/immunology specialists who strive to stay up for optimal health protection by focusing on patient management during the COVID-19 pandemic are necessary. As APAC passes through these challenging times of the COVID-19 pandemic, The Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) as an allergy/immunology community via its COVID-19 Task Force is carefully monitoring and updating Food and Drug Administration/Centers for Disease Control and Prevention/ WHO and other crucial scientific information on COVID-19 on its website COVID-19 resource section. Thus, the rising need for allergy treatment is likely to boost the market.

Market Overview and Dynamics

The Anaphylaxis treatment market in Asia Pacific is expected to grow from US$ 350.7 million in 2021 to US$ 664.0 million by 2028; it is estimated to grow at a CAGR of 9.6% from 2021 to 2028. Anaphylaxis is a severe, life‑threatening allergic reaction caused by vulnerability to allergens (foods, insect stings, or medicines) identified as a non-self by a human body. Typical indications of this condition include swallowing and breathing difficulties, skin redness and itching, accelerated heart rate, wheezing, rapid breathing rate, and lowering blood pressure. The incidence of anaphylaxis is increasing around the world. Therefore, the rising incidence of allergies is leading to surge in anaphylaxis cases. Due to the growing prevalence of allergies, the economic burden on healthcare systems in many countries is increasing. Thus, the burgeoning incidence of anaphylaxis is driving the growth of the market.

Key Market Segments

In terms of medication type, the epinephrine segment accounted for the largest share of the Asia Pacific anaphylaxis treatment market in 2020. In terms of route of administration, the parenteral segment accounted for the largest share of the Asia Pacific anaphylaxis treatment market in 2020. In terms of allergy type, the food allergy segment accounted for the largest share of the Asia Pacific anaphylaxis treatment market in 2020. In terms of distribution channel, the retail pharmacies segment held a larger market share of the anaphylaxis treatment market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the anaphylaxis treatment market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Amneal Pharmaceuticals Inc., Mylan N.V., Abbott, Pfizer Inc., Glaxosmithkline Plc., Merck and Co., Inc., Teva Pharmaceutical Industries Ltd., and ALK-ABELLó.

Reasons to buy report

• To understand the Asia Pacific anaphylaxis treatment market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Asia Pacific anaphylaxis treatment market
• Efficiently plan M&A and partnership deals in Asia Pacific Anaphylaxis treatment market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Asia Pacific Anaphylaxis treatment market
• Obtain market revenue forecast for market by various segments from 2021-2028 in Asia Pacific region.

ASIA PACIFIC ANAPHYLAXIS TREATMENT MARKET SEGMENTATION

By Medication Type

• Epinephrine
• Antihistamines
• Steroids
• Beta-Agonist
• Others

By Route of Administration

• Parenteral
• Oral
• Others

By Allergy Type

• Food Allergy
• Medications
• Insect Stings
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Country

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

Companies Mentioned

1. Amneal Pharmaceuticals Inc.
2. Mylan N.V.
3. Abbott
4. Pfizer Inc.
5. Glaxosmithkline Plc.,
6. Merck And Co., Inc.
7. Teva Pharmaceutical Industries Ltd.        
8. ALK-ABELLó   

Asia Pacific Anaphylaxis Treatment Market Strategic Insights

Asia Pacific Anaphylaxis Treatment Market Segmentation Analysis

Asia Pacific Anaphylaxis Treatment Market Report Highlights

Asia Pacific Anaphylaxis Treatment Report Scope

Asia Pacific Anaphylaxis Treatment Market Country and Regional Insights